The Science
What is the Tesamorelin / Ipamorelin 10/2 Blend?
Tesamorelin is a stabilized analog of growth hormone-releasing hormone (GHRH 1-44) with a trans-3-hexenoyl modification that extends its plasma half-life and resistance to dipeptidyl peptidase-IV cleavage.
Ipamorelin is a selective ghrelin receptor (GHS-R1a) pentapeptide secretagogue that stimulates GH release without significantly elevating cortisol or prolactin.
Tesamorelin's most distinctive research finding is its preferential reduction of visceral adipose tissue (VAT) in HIV-associated lipodystrophy populations.
Laboratory Observations
Key Observed Effects in Research
Visceral Adipose Reduction
Tesamorelin clinical research shows targeted reduction of visceral fat depots.
IGF-1 Elevation
Studies report sustained IGF-1 increases following Tesamorelin administration.
Amplified GH Pulses
Co-administration with a ghrelin mimetic enhances pituitary response in laboratory assays.
Favorable Hormonal Profile
Ipamorelin's selectivity preserves the neutral hormonal profile.
Mechanism of Action
GHRH-Weighted Dual Stimulation
The 10:2 ratio favors GHRH-axis dominance, with Ipamorelin acting as a smaller amplifying co-stimulus.
Stabilized GHRH Signal
Tesamorelin engages pituitary GHRH receptors with extended plasma exposure compared to native GHRH.
Visceral Fat Pathway
Tesamorelin's clinical signature includes preferential VAT reduction in published trials.
Selective Profile
Ipamorelin's receptor selectivity avoids cortisol and prolactin elevation.
Research-Only Notice
2X Blend Tesamorelin (10mg) / Ipamorelin (2mg) is categorized by the FDA as for research-purposes-only. It is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. The information above summarizes effects observed in laboratory studies to date and is provided strictly for scientific and educational reference.